The use of cyclical etidronate in osteoporosis: Changes after completion of 3 years treatment

British Journal of Rheumatology

Volumn 37, Issue 1, 1998, Pages 51-56

  Fairney, A ^a   Kyd, P ^b   Thomas, E ^b   Wilson, J ^b  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

Bone cell markers; Bone density; Completion of treatment; Cyclical editronate; Osteoporosis

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; ETIDRONIC ACID; OSTEOCALCIN;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE REMODELING; BONE TURNOVER; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; FEMUR NECK; FRACTURE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; OSTEOPOROSIS; PRIORITY JOURNAL;

EID: 0031825060     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/37.1.51     Document Type: Article

References (15)

1. Storm T, Thamsborg G, Steiniche T et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990;322:1265-71.
2. Watts NB, Harris ST, Genant HK et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990;323:73-9.
3. Watts NB, Miller PD, Licata AA et al. Seven years of cyclical etidronate: continued improvement in spine BMD and progressive decline in vertebral fracture incidence. Bone 1995;17:617.
4. Storm T, Kollerup G, Thamsborg G et al. Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis. J Rheumatol 1996;23:1560-4.
5. Miller PD, Erickson AL. Long term intermittent cyclical etidronate therapy for postmenopausal osteoporosis. Calcif Tissue Int 1995;56:493.
6. Lindsay R, Tohme JF. Oestrogen treatment of established postmenopausal osteoporosis. Obstet Gynaecol 1990;76:290-5.
7. Boyce BF, Smith L, Fogelman I et al. Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease. Lancet 1984;1:821-4.
8. Gibbs CJ, Aaron JE, Peacock M. Osteomalacia in Paget's disease treated with short term, high dose sodium etidronate. Br Med J 1986;292:1227-9.
9. Ott SM, Woodson GC, Huffer WE et al. Bone histomorphometric changes after cyclic therapy with phosphate and etidronate disodium in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 1994;78:968-72.
10. Heaney R. Estrogen-calcium interactions in the menopause: a quantitative description. Bone Mineral 1990; 11:67-84.
11. Felson DT, Yuquig Y, Hannan MT et al. The effect of post-menopausal therapy on bone density in elderly women. N Engl J Med 1993;329:1141-6.
12. Landman JO, Hamdy NAT, Pauwels EKJ, Papapoulos SE. Skeletal metabolism in patients with osteoporosis after discontinuation of long term treatment with oral Pamidronate. J Clin Endocrinol Metab 1995;80:3465-8.
13. Rossini M, Gatti D, Zamberlan N, Braga V, Dorizzi R, Adami S. Long term effects of a treatment course with oral alendronate of postmenopausal osteoporosis. J Bone Miner Res 1994;9:1833-7.
14. Rodan GA, Fleisch HA. Bisphosphonates: mechanism of action. J Clin Invest 1996;97:2692-6.
15. Vitte C, Fleisch HA, Guenther HL. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology 1996;137:2324-33.